WT1 and neoplasm: The efficacy of the combined HAGE/WT1 ImmunoBody® vaccines was then tested in both prophylactic and therapeutic settings in female HHDII/DR1 mice (n=10/group) using the aggressive hB16/HAGE+/Luc+ tumour.